U.S. Markets close in 4 hrs 55 mins

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
322.11+2.43 (+0.76%)
As of 11:04AM EST. Market open.

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200

IndustryDiagnostics & Research
Full Time Employees3,900

Key Executives

NameTitlePayExercisedYear Born
Mr. Kevin R. SayerExec. Chairman, CEO & Pres2.09MN/A1958
Mr. Quentin S. BlackfordCFO & COO1.17MN/A1979
Mr. Steven R. PacelliExec. VP of Strategy & Corp. Devel.873.62kN/A1972
Mr. Andrew K. BaloExec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel.875.97kN/A1948
Mr. Richard B. DoubledayExec. VP & Chief Commercial Officer930.08kN/A1963
Mr. Jereme SylvainSr. VP of Fin., Chief Accounting Officer & Corp. ControllerN/AN/A1980
Mr. Jacob Steven LeachExec. VP & CTON/AN/A1978
Mr. Sean ChristensenSr. Investor Relations Mang.N/AN/AN/A
Mr. Patrick Michael MurphyExec. VP & Chief Legal OfficerN/AN/A1979
Ms. Sadie M. SternExec. VP & Chief HR OfficerN/AN/A1975
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; a collaboration with Companion Medical, Inc.; and a development and commercialization agreement with Tandem Diabetes Care, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 2. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.